Q32 Bio Inc. (FWB:DB0) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Closed: US$200M raised · US$18.25 a share · Morgan Stanley +4 Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Cantor (co-lead), Oppenheimer & Co., H.C. Wainwright & Co. Use of proceeds: With existing cash, fund operations through topline Phase 3 results of the planned registration-directed bempikibart program in severe or very severe AA | Aug 5, 2026 |
| At-the-market programme of common stock Tranche closed: US$14.2M raised | May 5, 2026 |
| Registered direct offering of common stock and pre-funded warrants Announced: US$10.5M · US$3.9 a share Use of proceeds: Working capital, including research, clinical development and commercialization, and advancing bempikibart into future alopecia areata trials | Feb 17, 2026 |